Amundi Buys 111,872 Shares of Glaukos Corporation $GKOS

Amundi raised its stake in Glaukos Corporation (NYSE:GKOS - Free Report) by 96.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 227,290 shares of the medical instruments supplier's stock after buying an additional 111,872 shares during the period. Amundi owned 0.40% of Glaukos worth $22,370,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its position in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 158 shares in the last quarter. Whipplewood Advisors LLC boosted its position in Glaukos by 3,957.1% in the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 277 shares in the last quarter. First Horizon Advisors Inc. boosted its position in Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 159 shares in the last quarter. Versant Capital Management Inc boosted its position in Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 327 shares in the last quarter. Finally, CoreCap Advisors LLC boosted its position in Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Trading Down 3.5%

NYSE GKOS traded down $3.20 during mid-day trading on Wednesday, reaching $87.72. 866,980 shares of the stock were exchanged, compared to its average volume of 636,688. Glaukos Corporation has a one year low of $77.10 and a one year high of $163.71. The stock has a 50 day simple moving average of $94.22 and a 200-day simple moving average of $96.34. The stock has a market cap of $5.03 billion, a P/E ratio of -53.16 and a beta of 0.77. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same quarter last year, the firm earned ($0.52) earnings per share. Glaukos's quarterly revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on GKOS. UBS Group lifted their price target on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Wells Fargo & Company raised their target price on Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Mizuho set a $130.00 target price on Glaukos in a research report on Thursday, July 31st. BTIG Research reaffirmed a "buy" rating and set a $118.00 target price on shares of Glaukos in a research report on Wednesday. Finally, William Blair raised Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.83.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.